中国临床药理学与治疗学2025，Vol.30Issue(2)：159-170,12.DOI:10.12092/j.issn.1009-2501.2025.02.002
胆管癌精准诊疗进展及前沿
Advances in precision diagnosis and treatment of cholangiocarcinoma
摘要
Abstract
Cholangiocarcinoma(CCA)is a highly aggressive and heterogeneous biliary malignancy characterized by challenges in early diagnosis,limit-ed efficacy of traditional chemotherapy,and poor prognosis.Due to its significant heterogeneity at the genomic,epigenetic,and molecular levels,mo-lecular testing and targeted therapy have become increasingly important in CCA management,form-ing an integral part of the era of precision oncolo-gy.The development of next-generation sequenc-ing(NGS)has advanced research into the molecu-lar subtypes and therapeutic targets of CCA,includ-ing FGFR2 fusions/rearrangements,IDH1 muta-tions,and BRAF mutations.Recently,two phase Ⅲ clinical trials,TOPAZ-1 and KEYNOTE-966,have es-tablished the pivotal role of immunotherapy com-bined with chemotherapy in advanced CCA.While precision diagnosis and treatment in CCA have shown promising progress,this field remains in its exploratory phase and faces numerous challenges.This review summarizes recent advancements in the diagnosis,molecular targeted therapy,immuno-therapy,resistance mechanisms,and the develop-ment of novel strategies for CCA.关键词
胆管癌/靶向治疗/免疫治疗/精准诊疗Key words
cholangiocarcinoma/targeted thera-py/immunotherapy/precision diagnosis and treat-ment分类
临床医学引用本文复制引用
陈祯美,陈进宏..胆管癌精准诊疗进展及前沿[J].中国临床药理学与治疗学,2025,30(2):159-170,12.基金项目
国家自然科学基金项目(82070655) （82070655）
上海市"科技创新行动计划"优秀学术带头人计划项目(22XD1400300) （22XD1400300）
